(ORGO) Organogenesis Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68621F1021
ORGO: Wound Care, Surgical, Sports Medicine
Organogenesis Holdings Inc. (NASDAQ:ORGO) is a leader in regenerative medicine, specializing in advanced wound care and surgical solutions. Founded in 1985 and headquartered in Canton, Massachusetts, the company has established a strong market presence with its innovative products. Their portfolio includes Affinity, Novachor, Apligraf, and Dermagraft, each designed to address specific wound care needs with preserved viable cells and growth factors. The company also offers biosynthetic matrices like FortiShield and PuraPly, enhancing surgical applications. Their distribution network spans hospitals, wound care centers, and ambulatory services, ensuring wide accessibility.
The companys pipeline includes promising products such as ReNu and PuraForce, targeting soft tissue healing and surgical reinforcement. These developments underscore their commitment to innovation in regenerative medicine.
3-Month Forecast: - Price Movement: Expect ORGO to trade between $2.90 and $3.20, influenced by the SMA 20 and SMA 50 indicating a potential downtrend but supported by the SMA 200 at $3.07. - Volatility: Low ATR of 0.17 suggests minimal price fluctuations, indicating stability. - Valuation: A P/S ratio of 0.88 may attract value investors, though the negative RoE of -2.65 warrants monitoring for profitability improvements. This forecast is based on technical indicators and fundamental analysis, providing a data-driven outlook for ORGOs performance.Additional Sources for ORGO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ORGO Stock Overview
| Market Cap in USD | 715m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2017-01-05 |
ORGO Stock Ratings
| Growth 5y | 6.11% |
| Fundamental | 5.14% |
| Dividend | 0.0% |
| Rel. Strength Industry | 91 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 5.24 USD |
| Fair Price DCF | 0.40 USD |
ORGO Dividends
No Dividends PaidORGO Growth Ratios
| Growth Correlation 3m | 60.1% |
| Growth Correlation 12m | 76.3% |
| Growth Correlation 5y | -57.6% |
| CAGR 5y | 5.02% |
| CAGR/Max DD 5y | 0.05 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | 64.31 |
| Beta | 1.22 |
| Volatility | 73.78% |
| Current Volume | 1039.3k |
| Average Volume 20d | 1063k |
As of March 15, 2025, the stock is trading at USD 5.01 with a total of 1,039,337 shares traded.
Over the past week, the price has changed by -2.81%, over one month by +35.41%, over three months by +41.13% and over the past year by +76.41%.
Neither. Based on ValueRay Fundamental Analyses, Organogenesis Holdings is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 5.14 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ORGO as of March 2025 is 5.24. This means that ORGO is currently overvalued and has a potential downside of 4.59%.
Organogenesis Holdings has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ORGO.
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ORGO Organogenesis Holdings will be worth about 6.1 in March 2026. The stock is currently trading at 5.01. This means that the stock has a potential upside of +20.76%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6 | 19.8% |
| Analysts Target Price | 5 | -0.2% |
| ValueRay Target Price | 6.1 | 20.8% |